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Previews(Figure 1B). It is possible that APOC3 itself
promotes atherosclerosis (Ginsberg and
Brown, 2011), or alternatively, that
APOC3 retards clearance of atherogenic
lipoprotein remnants. If the lower levels
of TG in APOC3 carriers are atheroprotec-
tive, studies using other variants that
lower TG levels without affecting other
CHD risk factors should replicate the
association. Carriers of the APOC3 vari-
ants also have higher plasma levels of
HDL-C, which are inversely associated
with CHD. Ironically, Tybjærg-Hansen
and Kathiresan performed the key genetic
studies that showed plasma HDL-C levels
are not causally related to CHD risk
(Frikke-Schmidt et al., 2008; Voight
et al., 2012). Thus, it is unlikely that
HDL-C is conferring the cardioprotective
effect of the APOC3 mutations.
The identification of other sequence
variations that lower plasma TG levels
without altering other risk factors would
bolster the contention that TG lowering
is causally linked to reduction in CHD.
APOC3 may be an excellent therapeutic
target for patients with severe hypertri-
glyceridemia. These patients are at risk
of developing pancreatitis, a potentially
life-threatening disorder, and the arma-
mentarium of drugs to treat severe hy-
pertriglyceridemia is extremely limited.The high circulating levels of APOC3
(10–20 mg/dl) may limit the efficacy of
targeting APOC3 using antibody-based
therapies, but strategies that target
hepatic APOC3 mRNA may prove
efficacious.
Homozygotes for loss-of-function mu-
tations can provide important clues as
to the safety, as well as the efficacy, of
therapies targeting a specific protein.
Neither study identified any individuals
with total APOC3 deficiency. Identifica-
tion of such individuals would provide
reassurance that extreme pharmacolog-
ical inhibition of APOC3 would not have
unforeseen detrimental effects.
As these two studies attest, human
genetic studies have fueled a resurgence
of interest in lipid-modifying therapies
for CHD prevention. Studies using a
Mendelian randomization approach hold
the promise of identifying new thera-
peutic agents for CHD, but they must
address problems associated with pleiot-
ropy and account for effects of statin
treatment on plasma LDL-C levels.
Short-term reductions in LDL-C levels
due to statin therapy do not reflect lifetime
exposure to this atherogenic lipoprotein.
Mendelian randomization, although a
powerful approach, does not eliminate
all confounding factors.Cell Metabolism 20, SREFERENCES
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Nutrient availability and intermediate metabolism are increasingly recognized to govern stem cell behavior.
Oburoglu et al. (2014) now demonstrate that glutamine- and glucose-dependent nucleotide synthesis segre-
gate erythroid versus myeloid differentiation during hematopoietic stem cell specification, implicating a
metabolism-centric regulation of lineage choices.Flexibility in energy metabolism enables
cells to prioritizemetabolic pathways in or-
der to support stage-specific energetic de-
mands (Folmes et al., 2012). Interrogation
of stem cell metabolism has identifiedglycolysis as a key player in the mainte-
nance of stemness through provision of
energy and anabolic precursors (Folmes
et al., 2011), while oxidativemetabolismal-
lows for more efficient energy productionto match energy-demanding processes
of differentiating progeny (Chung et al.,
2007). Furthermore, individual metabolic
pathways underlying stem cell renewal
versus lineage specification are startingeptember 2, 2014 ª2014 Elsevier Inc. 389
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Figure 1. Glutamine and Glucose Metabolism Regulates Hematopoietic Stem Cell Lineage Sp
(A) Regulation of glutamine and glucose metabolism defines the ability of hematopoietic stem cells (HSCs) to
in vitro and in vivo. Glutamine uptake and glutaminolysis in support of de novo nucleotide biosynthesis and tric
critical for HSC erythroid lineage commitment. Alternative metabolic pathways that support nucleotide synth
glucose metabolism away from glycolysis toward the pentose phosphate pathway, promote erythropoiesis
(B) In contrast, impairing nucleotide biosynthesis during erythropoietin-induced differentiation by impeding ups
MSO), glutamine uptake, glutaminolysis (6-diao-5-oxo-L-norleucine, DON), transaminase reactions (aminooxy
pentose phosphate pathway (6-aminonicotinamide, 6-AN) skews lineage commitment away from erythroid an
osides rescues erythropoiesis, establishing the importance of de novo nucleotide biosynthesis for erythroid line
GPAT, glutamine phosphoribosylpyrophosphate amidotransferase; GS, glutamine synthetase; G-6-P, glucos
drogenase; PRA, phosphoribosylamine; PRPP, 5-phosphoribosyl-1-pyrophosphate.
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Previewsto be elucidated. For instance, PPARd-
dependent fatty acid oxidation supports
hematopoietic stem cell (HSC) pool main-
tenance through asymmetrical cell divi-
sion, with inhibition of this pathway leading
to HSC exhaustion due to symmetrical cell
division into differentiated progenitors (Ito
et al., 2012). Regulation of fatty acid
oxidation versus synthesismay thus repre-
sent a rheostat of stem cell fate (Folmes
et al., 2013), exemplified by the require-
ment for fatty acid synthesis in prolifer-
ating neural stem and progenitor cells
(Knobloch et al., 2013). However, meta-
bolic pathways that drive stem cells
along parallel lineage paths remain to be
defined, in line with metabolite-mediated
changes in the epigenetic state that prime
stem cells to undergo fate conversions
(Shyh-Chang et al., 2013a). A study pub-
lished in Cell Stem Cell now identifies
glutamine- and glucose-dependent nucle-
otide biosynthesis as critical for murine
and human HSC lineage specification,
thereby extending the metabolic blueprint
of stem cell identity and fate (Oburoglu
et al., 2014).
Mammalian cells predominantly utilize
glucose and glutamine as substrates to
produce energy and precursors for bio-
synthetic reactions. However, the glucose
transporter GLUT1 is not expressed in
hematopoietic progenitors and is only up-
regulated during late stages of human ery-
thropoiesis, suggesting that alternative
metabolic pathways may regulate HSC
lineage commitment. Oburoglu et al.
(2014) showed that HSCs and their pro-
genitors express the ASCT2 glutamine
transporter and found that knockdown of
ASCT2 during erythropoietin (EPO)-
induced differentiation skewed lineage
commitment of HSCs away from the
erythroid lineage (Figure 1A) in favor of
the myeloid lineage (Figure 1B). In con-
trast, knockdown of GLUT1 did not impact
lineage distribution. As ASCT2 can trans-
port other amino acids in addition to gluta-
mine, the authors confirmed that inhibitionecification
differentiate into erythroid versus myeloid lineages
arboxylic acid cycle a-ketoglutarate generation are
esis, including 2-deoxyglucose (2-DG) shunting of
.
tream glutamine synthesis (methionine sulfoximine,
acetic acid, AOA), or blocking glucose entry into the
d toward myeloid fate. Supplementation with nucle-
age commitment. GDH, glutamine dehydrogenase;
e-6-phosphate; G6PD, glucose-6-phosphate dehy-
Cell Metabolism
Previewsof glutaminolysis by 6-diazo-5-oxo-L-nor-
leucine (DON) directed lineage commit-
ment to the myeloid fate, while inhibition
of glucose utilization by 2-deoxyglucose
(2-DG) promoted the erythroid fate (Fig-
ure 1). Compensated by intracellular gluta-
mine synthesis, removal of extracellular
glutamine had little effect on erythropoi-
esis. Impairing glutaminolysis attenuated
the stimulating effect of 2-DG on erythroid
commitment, indicating the dominant na-
ture of glutamine catabolism.
Using simultaneous tracing of gluta-
mine carbons and nitrogens, the authors
identified specific glutamine-dependent
metabolic pathways critical for erythro-
genesis, including a transaminase-depen-
dent increase in a-ketoglutarate, as well
as a stimulation of de novo purine and py-
rimidine nucleotide synthesis in response
to EPO-induced erythropoiesis (Oburoglu
et al., 2014). Blocking transaminases and
nucleotide synthesis impaired erythropoi-
esis, a defect rescued by a cell-permeable
ester of a-ketoglutarate and nucleoside
supplementation, respectively. Concomi-
tant blockade of both pathways was only
rescued by replenishing nucleosides, es-
tablishing the prevailing role of gluta-
mine-dependent nucleotide biosynthesis
for erythroid commitment (Figure 1A). In
addition, the pentose phosphate path-
way, which is elevated in EPO-treated
cells and augmented by 2-DG treatment,
may drive nucleotide biosynthesis and
represents a potential mechanism by
which 2-DG promotes erythroid commit-
ment (Figure 1A).
To determine the impact of glucose and
glutamine metabolism in vivo, Oburoglu
and colleagues used a mouse model of
hemolytic anemia induced by phenyl-
hydrazine injection. Within 5 days of in-
duction, control and 2-DG-treated mice
showed rebound erythropoiesis, which
was attenuated by blocking glutaminoly-
sis with DON (Oburoglu et al., 2014). Sus-
tained anemia in DON-treated mice was
specific to erythrogenesis, as markers of
ongoing HSC differentiation (i.e., Gr1+
cells) were significantly elevated with little
effect on distribution of bone marrow pro-
genitors. The effect of blocking glutamine
metabolism was evident during stress, as
treatment of nonanemic mice with DON
did not impact progenitor distribution. In
newborn mice, which display active
hematopoietic lineage commitment, DON
treatment reduced the number of Ter119+erythroid progenitors and, within this
population, attenuated erythroid commit-
ment yet increased Gr1+ cells, while
2-DG treatment reduced myelomonocytic
lineages. Thus, the authors demonstrated
that the opposing regulatory roles of
glucose versus glutamine metabolism on
erythroid and myelomonocytic cell fate
extend in vivo.
Nucleotide biosynthesis, regardless of
its origin, appears therefore critical for
erythropoiesis (Figure 1), yet additional
studies are required to delineate whether
this observationmatches a higher anabolic
demand or whether these pathways
interact with epigenetic regulators to drive
cell fate. The ability to metabolically guide
lineage commitment provides insight into
the regulation of stem cell fate, opening
new avenues for investigation. For
example, can metabolic pathways offer
targets in guiding discrete fate choices
during lineage specification? What is the
timing of these events and how do these
pathways interact with genetics/epige-
netics to regulate cell fate? What is the
impact of metabolic regulation on stem
cell physiology and pathophysiology?
Growing evidence implicates that meta-
bolic changes occur early during transi-
tions between cellular fates (Folmes et al.,
2011), which may act by epigenetically
priming cells to support their ultimate fate
(Shyh-Chang et al., 2013a). Consistent
with this concept, glutaminolysis appears
critical during early erythroid commitment,
though it is dispensable once this lineage is
established (Oburoglu et al., 2014). It is
intriguing that modulating energy meta-
bolism may be exploited to facilitate
efficient progenitor generation for regener-
ative applications and that nutrient
changes in the niche can impact stem cell
function in health and disease. Recent
evidence indicates that reprogramming
cellular metabolism can enhance the
regenerative capacity of adult tissue.
Case in point: the reactivation of Lin28a
expression, which wanes during fetal
development and aging, enhances adult
tissue repair by accelerating glycolysis
and oxidative metabolism (Shyh-Chang
etal., 2013b). Indeed, inhibitionofoxidative
phosphorylation abrogates the benefits of
Lin28a, while induction of oxidative phos-
phorylation augments repair capacity.
This implicates that the decline in regener-
ative capacity with agingmay be a result of
compromised cellular metabolism leadingCell Metabolism 20, Sto impaired stem cell function, a concept
supported by evidence that caloric restric-
tion can enhance skeletal muscle stem cell
function by promoting oxidative meta-
bolism (Cerletti et al., 2012). Modulating
energy metabolism may thus offer thera-
peutic inroads for regenerative applica-
tions in aging and disease.
Linking discrete metabolic pathways to
differentiation of distinct lineages opens
the prospect of charting a metabolic
map underlying stem cell differentiation.
Building upon initial observations, future
studies are needed to identify metabolite
signals that influence lineage specifica-
tion and on resolving the mechanisms by
which metabolic pathways can interact
with (epi)genetic regulators to control
cell fate. In turn, modulation of energy
metabolism may serve for targeted deri-
vation of progenitor populations suitable
for regenerative therapies and for promot-
ing resident stem cell function to ensure
tissue self-repair.REFERENCES
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